Lecture Title: Signaling specific inhibitor of the CB1 receptor a new class of disease specific drugs
Date: Thursday 19 September 2019, 18.20-18.50
Pier-Vincenzo Piazza MD PhD also trained as a psychiatrist. He has been working full time on translational research since 1988. His particular field of expertise is the pathophysiology of behaviour and in particular addiction, which he has been studying for 30 years. From 2007 to 2017, he was the director of the Neurocentre Magendie (INSERM, U1215) in Bordeaux. The role of pregnenolone as a signaling specific allosteric inhibitor of the CB1 has been discovered by his research group who, based on this finding, has also developed a new pharmacological class now at the clinical stage.